Bio­gen fi­nal­ly pub­lish­es PhI­II re­sults for Aduhelm as crit­ics chas­tise low-rank­ing jour­nal, ‘gen­tle and un­re­veal­ing’ peer re­view

Bio­gen qui­et­ly an­nounced at a con­fer­ence in Spain to­day that a man­u­script of the Phase III re­sults for the com­pa­ny’s con­tro­ver­sial Alzheimer’s drug Aduhelm has fi­nal­ly been pub­lished in a tiny jour­nal with a con­flict­ed chief ed­i­tor, al­most a year af­ter the drug won its ac­cel­er­at­ed ap­proval.

The man­u­script was pub­lished Wednes­day in the Jour­nal of Pre­ven­tion of Alzheimer’s Dis­ease, a spokesper­son told End­points News, point­ing to the re­lease’s link to a com­pa­ny pre­sen­ta­tion to­day at the 2022 In­ter­na­tion­al Con­fer­ence on Alzheimer’s and Parkin­son’s Dis­eases.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.